DUBLIN--(BUSINESS WIRE)--May 15, 2018--The "Global Human Growth Hormones Deficiency (GHD) Drugs Market Assessment: Current Market, Pipeline Review, Clinical Trials, Market Potential - Forecast to 2023" report has been added to ResearchAndMarkets.com's offering.

The global human Growth Hormone Deficiency (GHD) Pipeline Drugs Market is projected to display a robust growth during 2018 - 2023, chiefly driven by low efficacy and poor dosing schedules of present drugs and improved safety and efficacy of investigational drugs.

The report has covered and analysed the present human Growth Hormone Deficiency (GHD) drugs in the market and has also analysed potential of four major pipeline drugs. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment evaluation.

The report presents the market potential of four major pipeline drugs (TransCon-hGH, Somapacitan, Somavaratan, Somatrogonmeant) for the treatment of human Growth Hormone Deficiency (GHD).

These four drugs that fall in the various categories of paediatrics and adults by end user have been recognized as being clinically effective in human Growth Hormone Deficiency treatment. Expected to be launched in the market within the next 4-5 years, these four potential drugs are likely to bring about major changes in the way Growth Hormone Deficiency is treated globally.

A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of Global human Growth Hormone Deficiency (GHD) Pipeline Drugs Market by assessing the potential of the four drugs that will be launched in the near future. Also, the report assesses the results of various clinical trials undertaken for each of the four drugs, the product profile, description and regulatory phase of each of the four drugs. Also, 7Ps Analysis (Patent, Phase, Pathway, Patient, Physician, Payer, Partner) has been done for each of the four drugs to present the current perspective.

Over the recent years, the human Growth Hormone Deficiency Drugs market is growing rapidly due to rising prevalence of patients with Growth Hormone Deficiency (GHD) around the world. Globally, the growth of human Growth Hormone Deficiency Drugs market is driven by increased penetration of drugs by market players coupled with introduction of new drugs with improved patient compliance.

Key Topics Covered:

1. Research Methodology

2. Executive Summary

3. Growth Hormone Deficiency Drugs Product - An Overview

4. Diagnosis of Growth Hormone Deficiency (GHD)

5. Treatment of Growth Hormone Deficiency (GHD)

6. Global Growth Hormone Drugs Market

7. Global Growth Hormone Deficiency Drugs Market

8. Global Growth Hormone Deficiency Drugs Market, By End User

9. Global Growth Hormone Deficiency Drugs Market: Regional Analysis

10. Global Growth Hormone Deficiency Drugs Market: Country Analysis

11. Human Growth Hormone Deficiency (hGHD) Pipeline Drugs Coverage

12. Company Profiles

Ascendis Pharma A/S Novo Nordisk A/S Versartis Inc. Opko Health Inc. Pfizer Inc.

For more information about this report visit https://www.researchandmarkets.com/research/jpqxbj/global_human?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180515005738/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Clinical Trials,Endocrine and Metabolic Disorders Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 05/15/2018 06:25 AM/DISC: 05/15/2018 06:25 AM

http://www.businesswire.com/news/home/20180515005738/en